Shanghai RAAS proposes cash dividend; awaits shareholder approval

Shanghai RAAS Blood Products (SZSE: 002252) has announced a proposal for its 2024 profit distribution, featuring a cash dividend of CNY 0.33 per 10 shares, pending shareholder approval. The company intends to distribute approximately CNY 218.54 million, representing 16.66% of the parent company's net profit after legal reserve deductions and 9.96% of the net profit attributable to shareholders. The decision to distribute profit was made by the board of directors and is consistent with the company's articles of association, regulatory guidelines on cash dividends, and the 2024-2026 shareholder return plan.